
Sigilon Therapeutics SGTX
Quarterly report 2023-Q2
added 05-23-2026
Sigilon Therapeutics Interest Expense 2011-2026 | SGTX
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Sigilon Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.29 M | 1.99 M | 1.2 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.29 M | 1.2 M | 1.83 M |
Quarterly Interest Expense Sigilon Therapeutics
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 310 K | 611 K | - | 606 K | 543 K | 491 K | - | 499 K | 494 K | 488 K | - | 293 K | 196 K | 208 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 611 K | 196 K | 431 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
9.34 K | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M | ||
|
Happiness Biotech Group Limited
HAPP
|
262 K | - | 1.35 % | $ 17.8 M | ||
|
AgeX Therapeutics
AGE
|
51 K | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
722 K | - | - | $ 866 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
16.4 M | - | - | $ 2.18 B | ||
|
Genfit SA
GNFT
|
4.68 M | - | 2.54 % | $ 160 B | ||
|
Alpine Immune Sciences
ALPN
|
98 K | - | - | $ 2.17 B | ||
|
ASLAN Pharmaceuticals Limited
ASLN
|
442 K | - | -14.27 % | $ 1.7 M | ||
|
Athira Pharma
ATHA
|
1.24 M | - | - | $ 269 M | ||
|
Coherus BioSciences
CHRS
|
9 M | $ 1.38 | -3.17 % | $ 162 M | ||
|
Galera Therapeutics
GRTX
|
11.4 M | - | -32.59 % | $ 7.61 M | ||
|
CRISPR Therapeutics AG
CRSP
|
86.6 M | $ 50.22 | -2.45 % | $ 4.52 B | ||
|
Berkeley Lights
BLI
|
910 K | - | -7.31 % | $ 87 M | ||
|
Celldex Therapeutics
CLDX
|
927 K | $ 29.5 | -0.34 % | $ 1.96 B | ||
|
IMV
IMV
|
2.34 K | - | - | $ 13.1 M | ||
|
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
1.93 M | $ 0.7 | 0.91 % | $ 32 M | ||
|
Esperion Therapeutics
ESPR
|
3.49 M | $ 3.15 | 0.32 % | $ 655 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
354 K | - | -4.36 % | $ 27 M | ||
|
Eton Pharmaceuticals
ETON
|
1.06 M | $ 31.66 | 3.7 % | $ 852 M | ||
|
Freeline Therapeutics Holdings plc
FRLN
|
2.15 M | - | - | $ 384 M | ||
|
Gracell Biotechnologies
GRCL
|
6.74 M | - | - | $ 3.37 B | ||
|
Exelixis
EXEL
|
-198 K | $ 53.51 | 0.98 % | $ 14.5 B | ||
|
Advaxis
ADXS
|
28 K | - | -9.65 % | $ 45.9 M | ||
|
Forte Biosciences
FBRX
|
-396 K | $ 17.03 | 0.18 % | $ 221 M | ||
|
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
561 K | $ 2.97 | 0.38 % | $ 4.89 M | ||
|
Aptinyx
APTX
|
737 K | - | -39.0 % | $ 4.57 M | ||
|
Albireo Pharma
ALBO
|
3.69 M | - | -0.23 % | $ 916 M |